Elite Pharmaceuticals Files ANDA for Hydrocodone and Acetaminophen Combo
12 déc. 2016 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA)...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2017 and Provides Conference Call Information
09 nov. 2016 16h37 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 2nd Quarter 2017 Financial Results on November 10, 2016
07 nov. 2016 12h51 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Announces Development and License Agreement with SunGen Pharma LLC
29 août 2016 09h01 HE
|
Elite Pharmaceuticals, Inc.; SunGen Pharma, LLC
NORTHVALE, N.J., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Announces Development and License Agreement with SunGen Pharma LLC
29 août 2016 08h00 HE
|
Elite Pharmaceuticals, Inc.; SunGen Pharma, LLC
NORTHVALE, N.J., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals files ANDA to Market Generic Percocet
10 août 2016 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA)...
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2017 and Provides Conference Call Information
09 août 2016 16h20 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss SequestOx™ Complete Response Letter on Monday, July 18, 2016 at 8:30 AM EDT
16 juil. 2016 15h46 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 16, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
FDA Issues Complete Response Letter for SequestOx™ New Drug Application
15 juil. 2016 17h06 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 15, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that the U.S. Food and Drug Administration (the “FDA”) has...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2016 and Provides Conference Call Information
15 juin 2016 16h19 HE
|
Elite Pharmaceuticals, Inc.
Revenues Increased 150% Conference Call Scheduled for Monday, June 20 at 11:00 AM EDT NORTHVALE, N.J., June 15, 2016 ...